Background: Peptoniphilus species are Gram-positive anaerobic cocci that are commensals of the human vagina and gut.
Methods And Results: We describe a case of mixed Escherichia coli and Peptoniphilus spp. osteomyelitis identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry as Peptoniphilus harei and present a short literature review.
Conclusion: To our knowledge, only six cases of P. harei osteomyelitis have been reported to date.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17843286.2020.1783908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors associated with treatment response in chronic nonbacterial osteomyelitis at a single center: a retrospective cohort study.
Pediatr Rheumatol Online J
January 2025
Division of Pediatric Rheumatology, Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA.
Background: NSAIDs are commonly used as first line therapy in chronic nonbacterial osteomyelitis (CNO) but are not effective for all patients. The objective of this study was to identify clinical variables associated with NSAID monotherapy response versus requiring second-line medication in a single-center cohort of patients with CNO.
Methods: The charts of children with CNO who attended a CNO clinic at a quaternary care center between 1/1/05 and 7/31/21 were retrospectively reviewed.
Development and validation of a prognostic nomogram model for severe osteomyelitis patients.
Sci Rep
January 2025
Department of Pediatric Surgery, Women and Children's Hospital Affiliated to Ningbo University, No. 339 Liuting Street, Ningbo, 315012, Zhejiang Province, China.
After severe infection in osteomyelitis patients in the Intensive Care Unit (ICU), there's a higher risk of mortality. However, limited research exists on predicting prognosis. Develop a predictive model for 1-year mortality risk in ICU-admitted osteomyelitis patients to inform clinical diagnosis and treatment.
View Article and Find Full Text PDFDeciphering pathogenicity and virulence of the first isolate from diabetic foot osteomyelitis.
Front Cell Infect Microbiol
January 2025
VBIC, INSERM U1047, University of Montpellier, Montpellier, France.
Introduction: This study identifies as a new coagulase-negative staphylococcal species isolated from diabetic foot osteomyelitis (DFOM) and provides an in-depth analysis of its pathogenic and virulence profile, as well as demonstrating its potential to cause infection.
Methods: The NSD001 strain was examined for its planktonic growth, biofilm production, and phagocytosis rates in murine macrophages compared to NSA739. Additionally, persistence and replication within human osteoblasts were investigated, while the zebrafish embryo model was employed to assess virulence.
Prevalence of Complications Due to Transphyseal Hematogenous Osteomyelitis.
J Bone Joint Surg Am
December 2024
Pediatric Orthopaedic Unit, Pediatric Surgery Service, Geneva University Hospitals, Geneva, Switzerland.
Background: Transphyseal hematogenous osteomyelitis (THO) is a common infectious condition, being present in 25% of patients with hematogenous osteomyelitis. A large proportion of pediatric hematogenous osteomyelitis infections can spread through the growth cartilage and therefore may be potentially responsible for growth disorders, leading to limb-length discrepancy or angular deformities. The purpose of the present study was to identify both the prevalence of complications caused by transphyseal osteomyelitis and factors influencing their occurrence.
View Article and Find Full Text PDFImpact of a nurse practitioner-led dedicated outpatient parenteral antibiotic therapy clinic on patient outcomes and administrative workload: a retrospective cohort study.
Ther Adv Infect Dis
December 2024
Division of Infectious Diseases, University of Toledo College of Medicine and Life Sciences, 3000 Arlington Avenue, Mail Stop 1186, Toledo, OH 43614, USA.
Background: Outpatient parenteral antibiotic therapy (OPAT) enhances patient safety, improves outcomes, and reduces healthcare costs by decreasing 30-day readmissions and adverse events. However, the optimal structure and follow-up protocols for OPAT programs remain undefined. Identifying high-risk patients for readmission and managing adverse drug events (ADEs) are critical components of OPAT care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!